Gtx, Our Mission, Our Focus
GTx is a company of pioneering and driven individuals who are delivering better medicines with new science through established pathways.
Our mission is to discover and develop novel, selective small molecules for the treatment of cancer and serious medical conditions.
We are focused on the development of small molecules that selectively modulate the effects of androgens and estrogens.
We are developing enobosarm (Ostarine®; GTx-024), a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. Based on recent clinical studies, we also are evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important.
GTx is also developing Capesaris® (GTx-758), a selective ER alpha agonist, as a hormonal therapy for men with advanced prostate cancer.